Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338172 | 0.92 | HCRTR1 (0.49) | HCRTR1HCRTR2ESR1MAPTMAPK10 | |
| SCHEMBL3415069 | 0.89 | HCRTR1 (0.45) | HCRTR1HCRTR2ESR1MAPTMAPK10 | |
| SCHEMBL1338286 | 0.88 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL1341324 | 0.88 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL1340421 | 0.86 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL1340759 | 0.85 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL1340390 | 0.85 | HCRTR1 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL1338369 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2ALDH1A1NPC1TSHR | |
| SCHEMBL1338375 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2ALDH1A1NPC1TSHR | |
| SCHEMBL1338296 | 0.84 | HCRTR1 (0.57) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | claimed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885ESR1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.